Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823412 | 0.85 | HSD11B1 (0.41) | HSD11B1HSD11B2CXCR3USP30AR | |
| SCHEMBL2826339 | 0.85 | HSD11B1 (0.41) | HSD11B1HSD11B2CXCR3USP30AR | |
| SCHEMBL2833018 | 0.84 | HSD11B1 (0.53) | HSD11B1HSD11B2 | |
| SCHEMBL2823665 | 0.83 | HSD11B1 (0.39) | HSD11B1HSD11B2 | |
| SCHEMBL2830595 | 0.80 | HSD11B1 (0.45) | HSD11B1HSD11B2CXCR3USP30AR | |
| SCHEMBL2824511 | 0.75 | HSD11B1 (0.45) | HSD11B1HSD11B2 | |
| SCHEMBL2824507 | 0.75 | HSD11B1 (0.51) | HSD11B1HSD11B2 | |
| SCHEMBL2831637 | 0.75 | HSD11B1 (0.33) | HSD11B1HSD11B2GPR6 | |
| SCHEMBL2831638 | 0.75 | HSD11B1 (0.33) | HSD11B1HSD11B2GPR6 | |
| SCHEMBL2830115 | 0.74 | HSD11B1 (0.52) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | claimed |
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | HSD11B1 2/4885HSD11B2 1/4885CXCR3 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.